Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News |  Antibody Contract Manufacturing Market, 2020-2030Roots Analysis has announced the addition of the "Antibody Contract Manufacturing Market, 2020-2030" report to its list of offerings.
By: Roots Analysis Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production. Further, prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing. To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this link Key Market Insights Over 100 CMOs presently claim to offer manufacturing services for antibodies The antibody contract manufacturing market is currently dominated by the presence of small and mid-sized companies, which represent 70% of the industry stakeholders. It is also worth highlighting that more than 55% of CMOs claim to have the capabilities to manufacture antibodies across all scales of operation (preclinical, clinical and commercial). More than 90% service providers are focused on the production of monoclonal antibodies However, players based in Asia are now increasingly focusing on the development of bispecific antibodies for therapeutic use. It worth highlighting that close to 20% of the CMOs engaged in this domain claim to offer manufacturing services for both bispecific antibodies and antibody fragments. Europe has emerged as a key manufacturing hub for antibody-based products More than 120 manufacturing facilities have been established by various players, worldwide; of these, 40% are in Europe. Additionally, 40% of the total installed capacity is in Europe, followed by Asia. Some of the prominent regions in Asia include (in decreasing order of number of manufacturing facilities) China, South Korea, India, Japan and Taiwan. More than 90 partnership agreements have been inked between 2013 and 2019 Majority of these agreements were focused on manufacturing of various types of antibodies. Other popular types of collaboration models include process development and manufacturing agreements (22%), product development and manufacturing agreements (10%) and licensing agreements (7%). § Type of Antibodies § Monoclonal Antibodies § Bispecific Antibodies § ADCs For additional details, please visit https://www.rootsanalysis.com/ You may also be interested in the following titles: 1. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030 (https://www.rootsanalysis.com/ 2. Antibody Drug Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030 3. Antibody Drug Conjugates Market (5th Edition), 2019-2030 Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 gaurav.chaudhary@ End
|
| |||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number